These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 21322021)

  • 21. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.
    LeWitt PA; Poewe W; Elmer LW; Asgharnejad M; Boroojerdi B; Grieger F; Bauer L
    Clin Neuropharmacol; 2016; 39(2):88-93. PubMed ID: 26882318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.
    Trenkwalder C; Benes H; Poewe W; Oertel WH; Garcia-Borreguero D; de Weerd AW; Ferini-Strambi L; Montagna P; Odin P; Stiasny-Kolster K; Högl B; Chaudhuri KR; Partinen M; Schollmayer E; Kohnen R;
    Lancet Neurol; 2008 Jul; 7(7):595-604. PubMed ID: 18515185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease.
    Wang Y; Yang YC; Lan DM; Wu H-; Zhao ZX
    Sleep Breath; 2017 May; 21(2):319-325. PubMed ID: 27726069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study.
    Valldeoriola F; Salvador A; Gómez-Arguelles JM; Marey J; Moya M; Ayuga Á; Ramírez F
    Int J Neurosci; 2018 Apr; 128(4):369-375. PubMed ID: 29249180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study.
    Timmermann L; Oehlwein C; Ransmayr G; Fröhlich H; Will E; Schroeder H; Lauterbach T; Bauer L; Kassubek J
    Postgrad Med; 2017 Jan; 129(1):46-54. PubMed ID: 27883297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living.
    Sun W; Wang Q; Yang T; Feng C; Qu Y; Yang Y; Li C; Sun Z; Asakawa T
    Neurol Sci; 2022 Oct; 43(10):5821-5837. PubMed ID: 35691972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
    Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
    J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Night-time use of rotigotine in advanced Parkinson's disease.
    Canesi M; Mariani CB; Isaias IU; Pezzoli G
    Funct Neurol; 2010; 25(4):201-4. PubMed ID: 21388580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease.
    Woitalla D; Dunac A; Safavi A; Ceravolo MG; Gomez Esteban JC; Pavese N; Asgharnejad M; Joeres L; Schuller JC; Chaudhuri KR
    Expert Opin Pharmacother; 2018 Jun; 19(9):937-945. PubMed ID: 29916262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.
    Jankovic J; Watts RL; Martin W; Boroojerdi B
    Arch Neurol; 2007 May; 64(5):676-82. PubMed ID: 17502466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Rotigotine plus intensive and goal-based rehabilitation versus Rotigotine alone in "de-novo" Parkinsonian subjects: a randomized controlled trial with 18-month follow-up.
    Ferrazzoli D; Ortelli P; Riboldazzi G; Maestri R; Frazzitta G
    J Neurol; 2018 Apr; 265(4):906-916. PubMed ID: 29442177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.
    LeWitt PA; Boroojerdi B; Surmann E; Poewe W; ;
    J Neural Transm (Vienna); 2013 Jul; 120(7):1069-81. PubMed ID: 23208198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
    Poewe WH; Rascol O; Quinn N; Tolosa E; Oertel WH; Martignoni E; Rupp M; Boroojerdi B;
    Lancet Neurol; 2007 Jun; 6(6):513-20. PubMed ID: 17509486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.
    Garcia-Borreguero D; Allen R; Hudson J; Dohin E; Grieger F; Moran K; Schollmayer E; Smit R; Winkelman J
    Curr Med Res Opin; 2016; 32(1):77-85. PubMed ID: 26569149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
    Nomoto M; Mizuno Y; Kondo T; Hasegawa K; Murata M; Takeuchi M; Ikeda J; Tomida T; Hattori N
    J Neurol; 2014 Oct; 261(10):1887-93. PubMed ID: 25022939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.
    Nomoto M; Iwaki H; Kondo H; Sakurai M
    J Neurol; 2018 Feb; 265(2):253-265. PubMed ID: 29164312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline.
    Ghys L; Surmann E; Whitesides J; Boroojerdi B
    Expert Opin Pharmacother; 2011 Sep; 12(13):1985-98. PubMed ID: 21790503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.
    Giladi N; Boroojerdi B; Korczyn AD; Burn DJ; Clarke CE; Schapira AH;
    Mov Disord; 2007 Dec; 22(16):2398-404. PubMed ID: 17935234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of rotigotine on Parkinson's disease-related sleep disturbances.
    Antonini A; Calandrella D; Merello M; Koutsikos K; Pilleri M
    Expert Opin Pharmacother; 2013 Dec; 14(18):2571-80. PubMed ID: 24138154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.